Selected research
Industry Research
Pneumonia Vaccine Industry Research Report 2026
Market perspective
The global Pneumonia Vaccine market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Pneumonia Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Pneumonia Vaccine is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Pneumonia Vaccine is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Pneumonia Vaccine include Johnson & Johnson, Merck & Co., Inc., Pfizer Inc., Glaxosmithkline Plc., Zhifei Biologic, Walvax Biotechnology, Serum Institute of India Pvt. Ltd., Sanofi Pasteur and Royal (Wuxi) Bio-Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Pneumonia Vaccine market in terms of revenue (US$ million) and, where applicable, sales volume (doses), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/doses) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Pneumonia Vaccine Market by Company
Johnson & Johnson
Merck & Co., Inc.
Pfizer Inc.
Glaxosmithkline Plc.
Zhifei Biologic
Walvax Biotechnology
Serum Institute of India Pvt. Ltd.
Sanofi Pasteur
Royal (Wuxi) Bio-Pharmaceutical
Emergent Biosolutions
CSL Limited
Astrazeneca Plc.
Astellas Pharma Inc.
Pneumonia Vaccine Segment by Type
Pneumococcal Conjugate Vaccine (PCV13)
Pneumococcal Polysaccharide Vaccine (PPSV23)
Other
Pneumonia Vaccine Segment by Application
Sepsis
Meningitis
Pneumonia
Pneumonia Vaccine Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pneumonia Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Pneumonia Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pneumonia Vaccine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Pneumonia Vaccine manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Pneumonia Vaccine by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Pneumonia Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Pneumococcal Conjugate Vaccine (PCV13)
- Pneumococcal Polysaccharide Vaccine (PPSV23)
- Other
Applications
- Sepsis
- Meningitis
- Pneumonia
Companies covered
- Johnson & Johnson
- Merck & Co., Inc.
- Pfizer Inc.
- Glaxosmithkline Plc.
- Zhifei Biologic
- Walvax Biotechnology
- Serum Institute of India Pvt. Ltd.
- Sanofi Pasteur
- Royal (Wuxi) Bio-Pharmaceutical
- Emergent Biosolutions
- CSL Limited
- Astrazeneca Plc.
- Astellas Pharma Inc.
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Pneumonia Vaccine Market Size (2021-2032)
- 2.2.2 Global Pneumonia Vaccine Sales (2021-2032)
- 2.2.3 Global Pneumonia Vaccine Market Average Price (2021-2032)
- 2.3 Pneumonia Vaccine by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Pneumococcal Conjugate Vaccine (PCV13)
- 2.3.3 Pneumococcal Polysaccharide Vaccine (PPSV23)
- 2.3.4 Other
- 2.4 Pneumonia Vaccine by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Sepsis
- 2.4.3 Meningitis
- 2.4.4 Pneumonia
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Pneumonia Vaccine Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Pneumonia Vaccine Sales (doses) of Manufacturers (2021-2026)
- 3.3 Global Pneumonia Vaccine Revenue of Manufacturers (2021-2026)
- 3.4 Global Pneumonia Vaccine Average Price by Manufacturers (2021-2026)
- 3.5 Global Pneumonia Vaccine Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Pneumonia Vaccine, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Pneumonia Vaccine, Product Type & Application
- 3.8 Global Manufacturers of Pneumonia Vaccine, Established Date
- 3.9 Global Pneumonia Vaccine Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Johnson & Johnson
- 4.1.1 Johnson & Johnson Company Information
- 4.1.2 Johnson & Johnson Business Overview
- 4.1.3 Johnson & Johnson Pneumonia Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Johnson & Johnson Pneumonia Vaccine Product Portfolio
- 4.1.5 Johnson & Johnson Recent Developments
- 4.2 Merck & Co., Inc.
- 4.2.1 Merck & Co., Inc. Company Information
- 4.2.2 Merck & Co., Inc. Business Overview
- 4.2.3 Merck & Co., Inc. Pneumonia Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Merck & Co., Inc. Pneumonia Vaccine Product Portfolio
- 4.2.5 Merck & Co., Inc. Recent Developments
- 4.3 Pfizer Inc.
- 4.3.1 Pfizer Inc. Company Information
- 4.3.2 Pfizer Inc. Business Overview
- 4.3.3 Pfizer Inc. Pneumonia Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Pfizer Inc. Pneumonia Vaccine Product Portfolio
- 4.3.5 Pfizer Inc. Recent Developments
- 4.4 Glaxosmithkline Plc.
- 4.4.1 Glaxosmithkline Plc. Company Information
- 4.4.2 Glaxosmithkline Plc. Business Overview
- 4.4.3 Glaxosmithkline Plc. Pneumonia Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Glaxosmithkline Plc. Pneumonia Vaccine Product Portfolio
- 4.4.5 Glaxosmithkline Plc. Recent Developments
- 4.5 Zhifei Biologic
- 4.5.1 Zhifei Biologic Company Information
- 4.5.2 Zhifei Biologic Business Overview
- 4.5.3 Zhifei Biologic Pneumonia Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Zhifei Biologic Pneumonia Vaccine Product Portfolio
- 4.5.5 Zhifei Biologic Recent Developments
- 4.6 Walvax Biotechnology
- 4.6.1 Walvax Biotechnology Company Information
- 4.6.2 Walvax Biotechnology Business Overview
- 4.6.3 Walvax Biotechnology Pneumonia Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Walvax Biotechnology Pneumonia Vaccine Product Portfolio
- 4.6.5 Walvax Biotechnology Recent Developments
- 4.7 Serum Institute of India Pvt. Ltd.
- 4.7.1 Serum Institute of India Pvt. Ltd. Company Information
- 4.7.2 Serum Institute of India Pvt. Ltd. Business Overview
- 4.7.3 Serum Institute of India Pvt. Ltd. Pneumonia Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Serum Institute of India Pvt. Ltd. Pneumonia Vaccine Product Portfolio
- 4.7.5 Serum Institute of India Pvt. Ltd. Recent Developments
- 4.8 Sanofi Pasteur
- 4.8.1 Sanofi Pasteur Company Information
- 4.8.2 Sanofi Pasteur Business Overview
- 4.8.3 Sanofi Pasteur Pneumonia Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Sanofi Pasteur Pneumonia Vaccine Product Portfolio
- 4.8.5 Sanofi Pasteur Recent Developments
- 4.9 Royal (Wuxi) Bio-Pharmaceutical
- 4.9.1 Royal (Wuxi) Bio-Pharmaceutical Company Information
- 4.9.2 Royal (Wuxi) Bio-Pharmaceutical Business Overview
- 4.9.3 Royal (Wuxi) Bio-Pharmaceutical Pneumonia Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Royal (Wuxi) Bio-Pharmaceutical Pneumonia Vaccine Product Portfolio
- 4.9.5 Royal (Wuxi) Bio-Pharmaceutical Recent Developments
- 4.10 Emergent Biosolutions
- 4.10.1 Emergent Biosolutions Company Information
- 4.10.2 Emergent Biosolutions Business Overview
- 4.10.3 Emergent Biosolutions Pneumonia Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Emergent Biosolutions Pneumonia Vaccine Product Portfolio
- 4.10.5 Emergent Biosolutions Recent Developments
- 4.11 CSL Limited
- 4.11.1 CSL Limited Company Information
- 4.11.2 CSL Limited Business Overview
- 4.11.3 CSL Limited Pneumonia Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 CSL Limited Pneumonia Vaccine Product Portfolio
- 4.11.5 CSL Limited Recent Developments
- 4.12 Astrazeneca Plc.
- 4.12.1 Astrazeneca Plc. Company Information
- 4.12.2 Astrazeneca Plc. Business Overview
- 4.12.3 Astrazeneca Plc. Pneumonia Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Astrazeneca Plc. Pneumonia Vaccine Product Portfolio
- 4.12.5 Astrazeneca Plc. Recent Developments
- 4.13 Astellas Pharma Inc.
- 4.13.1 Astellas Pharma Inc. Company Information
- 4.13.2 Astellas Pharma Inc. Business Overview
- 4.13.3 Astellas Pharma Inc. Pneumonia Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Astellas Pharma Inc. Pneumonia Vaccine Product Portfolio
- 4.13.5 Astellas Pharma Inc. Recent Developments
5 Global Pneumonia Vaccine Market Scenario by Region
- 5.1 Global Pneumonia Vaccine Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Pneumonia Vaccine Sales by Region: 2021-2032
- 5.2.1 Global Pneumonia Vaccine Sales by Region: 2021-2026
- 5.2.2 Global Pneumonia Vaccine Sales by Region: 2027-2032
- 5.3 Global Pneumonia Vaccine Revenue by Region: 2021-2032
- 5.3.1 Global Pneumonia Vaccine Revenue by Region: 2021-2026
- 5.3.2 Global Pneumonia Vaccine Revenue by Region: 2027-2032
- 5.4 North America Pneumonia Vaccine Market Facts & Figures by Country
- 5.4.1 North America Pneumonia Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Pneumonia Vaccine Sales by Country (2021-2032)
- 5.4.3 North America Pneumonia Vaccine Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Pneumonia Vaccine Market Facts & Figures by Country
- 5.5.1 Europe Pneumonia Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Pneumonia Vaccine Sales by Country (2021-2032)
- 5.5.3 Europe Pneumonia Vaccine Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Pneumonia Vaccine Market Facts & Figures by Country
- 5.6.1 Asia Pacific Pneumonia Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Pneumonia Vaccine Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Pneumonia Vaccine Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Pneumonia Vaccine Market Facts & Figures by Country
- 5.7.1 South America Pneumonia Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Pneumonia Vaccine Sales by Country (2021-2032)
- 5.7.3 South America Pneumonia Vaccine Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Pneumonia Vaccine Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Pneumonia Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Pneumonia Vaccine Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Pneumonia Vaccine Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Pneumonia Vaccine Sales by Type (2021-2032)
- 6.1.1 Global Pneumonia Vaccine Sales by Type (2021-2032) & (doses)
- 6.1.2 Global Pneumonia Vaccine Sales Market Share by Type (2021-2032)
- 6.2 Global Pneumonia Vaccine Revenue by Type (2021-2032)
- 6.2.1 Global Pneumonia Vaccine Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Pneumonia Vaccine Revenue Market Share by Type (2021-2032)
- 6.3 Global Pneumonia Vaccine Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Pneumonia Vaccine Sales by Application (2021-2032)
- 7.1.1 Global Pneumonia Vaccine Sales by Application (2021-2032) & (doses)
- 7.1.2 Global Pneumonia Vaccine Sales Market Share by Application (2021-2032)
- 7.2 Global Pneumonia Vaccine Revenue by Application (2021-2032)
- 7.2.1 Global Pneumonia Vaccine Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Pneumonia Vaccine Revenue Market Share by Application (2021-2032)
- 7.3 Global Pneumonia Vaccine Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Pneumonia Vaccine Value Chain Analysis
- 8.1.1 Pneumonia Vaccine Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Pneumonia Vaccine Production Mode & Process
- 8.2 Pneumonia Vaccine Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Pneumonia Vaccine Distributors
- 8.2.3 Pneumonia Vaccine Customers
9 Global Pneumonia Vaccine Analyzing Market Dynamics
- 9.1 Pneumonia Vaccine Industry Trends
- 9.2 Pneumonia Vaccine Industry Drivers
- 9.3 Pneumonia Vaccine Industry Opportunities and Challenges
- 9.4 Pneumonia Vaccine Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst